Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients Receiving Heat Shock Protein Peptide Complex 96 Vaccination

Heat shock protein peptide complex 96 (HSPPC-96) has been proven to be a safe and preliminarily effective therapeutic vaccine in treating newly diagnosed glioblastoma multiforme (GBM) (NCT02122822). However, the clinical outcomes were highly variable, rendering the discovery of outcome-predictive bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yi, Li, Chunzhao, Chi, Xiaohan, Huang, Xijian, Gao, Hua, Ji, Nan, Zhang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321638/
https://www.ncbi.nlm.nih.gov/pubmed/35903678
http://dx.doi.org/10.3389/fonc.2022.865779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321638/
https://www.ncbi.nlm.nih.gov/pubmed/35903678
http://dx.doi.org/10.3389/fonc.2022.865779

Ejemplares similares